Risk factor
Low price volatility
Profitability factor
Overvalued vs peers
About
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, reasonab
Target Price
The average target price of SDZ.SW is 55 and suggests 9% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr
Buy
Sell